Cytek Biosciences (CTKB) Depreciation & Amortization (CF) (2020 - 2026)

Cytek Biosciences (CTKB) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 0.53% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 2.45% YoY), and the FY2025 full-year result was $7.6 million, up 5.09% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.9 million, down from $1.9 million in the prior quarter.
• Across five years, Depreciation & Amortization (CF) topped out at $1.9 million in Q3 2025 and bottomed at $72000.0 in Q3 2022.
• The 5-year median for Depreciation & Amortization (CF) is $1.8 million (2023), against an average of $1.5 million.
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) sank 61.9%; it then jumped 2354.17% in 2023.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $761000.0 in 2022, then soared by 114.32% to $1.6 million in 2023, then rose by 13.67% to $1.9 million in 2024, then climbed by 2.27% to $1.9 million in 2025, then slipped by 1.64% to $1.9 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $1.9 million (Q3 2025), per Business Quant data.

Peer Comparison